Clinical Trial Update: A Phase 2, Controlled, Double Blind, Randomized and Multicenter Study to Compare Efficacy and Safety of a Novel Topical Therapy (APT-001, Spinosad 1.8%) in Patients With Blepharitis. [Phase 2]

View source ↗

Summary

Phase 2, multicenter, randomized, double-blind study assessing the efficacy and safety of APT-001 (Spinosad 1.8%) topical therapy for blepharitis; recruitment i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Blepharitis

Drugs mentioned

• APT-001 (Spinosad 1.8%) topical therapy (Spinosad)

Snippet

Sponsor: Aperta Biosciences, LLC | Conditions: Blepharitis | Phase 2 | Status: RECRUITING